Top Markets
#1 QuantixAI QuantixAI +52.46%
#2 MowCat MowCat +27.53%
#3 Prom Prom +20.28%
#4 Wrapped STX (Velar) Wrapped STX (Velar) +20.21%
#5 Tutorial Tutorial +18.49%
#6 Versatize Coin Versatize Coin +16.67%
#7 StonkBroker StonkBroker +12.69%
#8 Wrapped NXM Wrapped NXM +11.40%
#9 Pons Pons +10.52%
#10 Nesa Nesa +10.02%
Coin of the day
QuantixAI QuantixAI
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
ZIOPHARM Oncology, Inc. ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology, Inc.

ZIOP
Classement en actions #20772
ZIOPHARM Oncology, Inc. is a clinical-stage biopharmaceutical firm dedicated to... ZIOPHARM Oncology, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing innovative immuno-oncology treatments for cancer patients. The company leverages its proprietary Sleeping Beauty platform, which employs non-viral genetic engineering to modify T-cells outside the body using a transposon/transposase system for subsequent infusion. Additionally, ZIOPHARM is advancing its Controlled IL-12 technology, designed to precisely regulate the expression of interleukin-12 (IL-12), a key immune system regulator, to direct the patient's immune response against cancer cells. Its pipeline features several promising therapeutic candidates, including T-cell receptor (TCR) plus T-cell therapies aimed at solid tumors, chimeric antigen receptor (CAR) T-cell therapies specifically targeting CD19 for hematologic malignancies, and Ad-RTS-hIL-12 combined with veledimex, a gene delivery system for controlled IL-12 production under investigation for treating recurrent adult glioblastoma multiforme. ZIOPHARM maintains strategic collaborations, including a licensing agreement with PGEN Therapeutics, Inc., and research and development agreements, alongside patent licensing, with institutions such as The University of Texas MD Anderson Cancer Center and the National Cancer Institute. The company's headquarters are located in Boston, Massachusetts.
Prix de l'action
$0.8657
Dernière synchronisation: 2022-01-26
Capitalisation boursière
$122.22M
Changement (1 jour)
-0.88%
Changement (1 an)
0.00%
Pays
US
Échange ZIOPHARM Oncology, Inc. (ZIOP)

Catégorie

Healthcare
Revenus pour ZIOPHARM Oncology, Inc. (ZIOP)
Revenus en Aug 2026 TTM : 0
Selon les derniers rapports financiers de ZIOPHARM Oncology, Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de 0. En 2026, l'entreprise a réalisé un chiffre d'affaires de 0 égal à le chiffre d'affaires de l'année 2026, qui était de 0. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour ZIOPHARM Oncology, Inc. de 2026 à 2026
Revenus à la fin de chaque année
Année Revenus Changez
Pas assez de données pour les dates fournies.
Revenus d’entreprises similaires ou concurrentes
Entreprise Revenus Différence de revenus Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH